‘Wave’ of healthcare bankruptcies predicted for 2018

Bankruptcy filings among healthcare companies more than tripled in 2017, according to Bloomberg, and there are signs that 2018 will bring more filings or debt restructuring from hospitals and other medical organizations.

Bloomberg reported several troubling signs which have created a “perfect storm” for the sector:

  • Chapter 11 bankruptcy filings by companies with more than $1 million in assets have set records in four of the last six quarters.
  • Bankruptcy activity in healthcare has increased by 123 percent since the end of 2010, compared to a 58 percent decline in all sectors.
  • Healthcare junk bonds have dropped 1.4 percent in November.

The hardest hit facilities will be private, rural hospitals, according to David Neier, a partner in the New York office of law firm Winston & Strawn. Many have struggled in recent years as the increasing prevalence of high-deductible health plans resulted in more patients being unable to pay their bills, resulting in more bad debt.

What may put them over the edge, Neier said, is the Affordable Care Act’s long-delayed cuts to Disproportionate Share Hospital (DSH) payments going into effect, which may “single-handedly throw hospitals into immediate financial distress—many operate on less than one day’s cash.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.